Henlius -Model HLX11 -Pertuzumab Injection

HLX11, recombinant anti-HER2 domain II humanised monoclonal antibody injection, a pertuzumab biosimilar. It can be used in combination with trastuzumab and chemotherapy for adjuvant treatment and neoadjuvant treatment for patients with HER2-positive BC and HER2-positive mBC. The first subject has been dosed in multi-centre phase 3 clinical trial of HLX11 for the neoadjuvant therapy in patients with HER2-positive, HR-negative early or locally advanced breast cancer.